大禹生物
(871970)
| 流通市值：3.85亿 | | | 总市值：8.14亿 |
| 流通股本：5270.44万 | | | 总股本：1.11亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 25,100,709.69 | 160,576,693.07 | 115,156,370.54 | 69,247,737.67 |
| 营业收入 | 25,100,709.69 | 160,576,693.07 | 115,156,370.54 | 69,247,737.67 |
| 二、营业总成本 | 30,762,109.13 | 168,953,762.4 | 125,215,153.85 | 78,135,397.06 |
| 营业成本 | 19,121,934.9 | 116,777,847.23 | 85,514,270.98 | 51,242,622.76 |
| 税金及附加 | 69,122.61 | 1,477,272.32 | 810,219.72 | 776,269.21 |
| 销售费用 | 3,227,327.55 | 18,730,984.45 | 14,164,333.56 | 9,922,636.49 |
| 管理费用 | 5,563,313.76 | 19,725,003.49 | 15,709,693.19 | 10,306,505.65 |
| 研发费用 | 2,226,327.07 | 10,260,570.09 | 7,749,700.05 | 5,210,733.62 |
| 财务费用 | 554,083.24 | 1,982,084.82 | 1,266,936.35 | 676,629.33 |
| 其中:利息费用 | 558,963.89 | 2,154,941.66 | 1,438,493.05 | 843,769.46 |
| 其中:利息收入 | 11,890.65 | 198,564.51 | 186,844.52 | 174,651.04 |
| 资产处置收益 | - | 299,352.14 | 299,352.14 | 299,352.14 |
| 资产减值损失(新) | - | -478,103.82 | -94,315.73 | -149,663.5 |
| 信用减值损失(新) | -17,948.13 | -552,502.88 | -211,263.03 | -179,076.71 |
| 其他收益 | 1,228,473.07 | 7,240,028.8 | 3,955,979.67 | 2,572,829.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -4,450,874.5 | -1,868,295.09 | -6,109,030.26 | -6,344,217.81 |
| 加:营业外收入 | 0.45 | 22,458 | 100,294.58 | 75,003.81 |
| 减:营业外支出 | - | 503,540.76 | 503,540.76 | 3,540.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -4,450,874.05 | -2,349,377.85 | -6,512,276.44 | -6,272,754.76 |
| 减:所得税费用 | - | -259,607.4 | -217,931.02 | -205,417.96 |
| 六、净利润 | -4,450,874.05 | -2,089,770.45 | -6,294,345.42 | -6,067,336.8 |
| 持续经营净利润 | -4,450,874.05 | -2,089,770.45 | -6,294,345.42 | -6,067,336.8 |
| 归属于母公司股东的净利润 | -4,450,874.05 | -2,089,770.45 | -6,294,345.42 | -6,067,336.8 |
| (一)基本每股收益 | -0.04 | -0.02 | -0.06 | -0.05 |
| (二)稀释每股收益 | -0.04 | -0.02 | -0.06 | -0.05 |
| 九、综合收益总额 | -4,450,874.05 | -2,089,770.45 | -6,294,345.42 | -6,067,336.8 |
| 归属于母公司股东的综合收益总额 | -4,450,874.05 | -2,089,770.45 | -6,294,345.42 | -6,067,336.8 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-26 | 2023-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |